Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 May;38(5):924–930. doi: 10.1128/aac.38.5.924

Effects of 2',3'-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis.

A Faraj 1, D A Fowler 1, E G Bridges 1, J P Sommadossi 1
PMCID: PMC188128  PMID: 7520683

Abstract

2',3'-Dideoxynucleosides (ddNs) including 3'-azido-3'-deoxythymidine (AZT), 3'-fluoro-3'-deoxythymidine (FLT), 3'-amino-3'-deoxythymidine (AMT), 2',3'-dideoxycytidine (ddC), and 2',3'-didehydro-3'-deoxythymidine (D4T) were tested for their effects on proliferation and differentiation of pluripotent progenitor cells (CD34+) purified from human bone marrow cells grown in liquid cultures. These highly purified progenitor cells undergo extensive proliferation during 14 days, with a marked differentiation during the last 7 days. These differentiated cells exhibit normal morphological features in response to specific hematopoietic growth factors of both erythroid and granulocyte-macrophage lineages, as demonstrated by flow cytometry cell phenotyping. The potencies of these ddNs in inhibiting proliferation of granulocyte-macrophage lineage cells were in the order FLT > AMT = ddC > AZT >> D4T, and the potencies in inhibiting proliferation of erythroid lineage cultures were in the order FLT > AMT > AZT > ddC >> D4T. The toxic effects of ddNs assessed in these liquid cultures were in agreement with data obtained by using semisolid cultures, demonstrating the consistency of these two in vitro hematopoietic systems toward ddN toxicity. ddC was toxic to CD34+ progenitor cells and/or cells in the early stages of differentiation, whereas the inhibitory effect of AZT on the erythroid lineage was predominantly observed on a more mature population of erythroid progenitors during the differentiation process. Slot blot analysis of granulocyte-macrophage cultures demonstrated that exposure to ddC and FLT was associated with a decrease in total mitochondrial DNA (mtDNA) content, suggesting that these two ddNs inhibit mtDNA synthesis. In contrast, no difference in the ratio of nuclear DNA to mtDNA was observed in cells exposed to toxic concentrations of AZT and AMT is not associated with an inhibition of mtDNA synthesis. This human pluripotent progenitor liquid culture system should permit detailed investigations of the cellular and molecular events involved in ddN-induced hematological toxicity.

Full text

PDF
924

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson S., Bankier A. T., Barrell B. G., de Bruijn M. H., Coulson A. R., Drouin J., Eperon I. C., Nierlich D. P., Roe B. A., Sanger F. Sequence and organization of the human mitochondrial genome. Nature. 1981 Apr 9;290(5806):457–465. doi: 10.1038/290457a0. [DOI] [PubMed] [Google Scholar]
  2. Bridges E. G., Faraj A., Sommadossi J. P. Inhibition of mammalian DNA polymerase-associated 3' to 5' exonuclease activity by 5'-monophosphates of 3'-azido-3'-deoxythymidine and 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1993 Apr 22;45(8):1571–1576. doi: 10.1016/0006-2952(93)90296-9. [DOI] [PubMed] [Google Scholar]
  3. Böttiger D., Ståhle L., Li S. L., Oberg B. Long-term tolerance and efficacy of 3'-azidothymidine and 3'-fluorothymidine treatment of asymptomatic monkeys infected with simian immunodeficiency virus. Antimicrob Agents Chemother. 1992 Aug;36(8):1770–1772. doi: 10.1128/aac.36.8.1770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chen C. H., Cheng Y. C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. J Biol Chem. 1989 Jul 15;264(20):11934–11937. [PubMed] [Google Scholar]
  5. Chen C. H., Cheng Y. C. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2',3'-dideoxycytidine. J Biol Chem. 1992 Feb 15;267(5):2856–2859. [PubMed] [Google Scholar]
  6. Chen C. H., Vazquez-Padua M., Cheng Y. C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol. 1991 May;39(5):625–628. [PubMed] [Google Scholar]
  7. Cheng Y. C., Gao W. Y., Chen C. H., Vazquez-Padua M., Starnes M. C. DNA polymerases versus HIV reverse transcriptase in AIDS therapy. Ann N Y Acad Sci. 1990;616:217–223. doi: 10.1111/j.1749-6632.1990.tb17842.x. [DOI] [PubMed] [Google Scholar]
  8. Chow F. P., Sutton P. A., Hamburger A. W. Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice. Br J Haematol. 1991 Feb;77(2):139–144. doi: 10.1111/j.1365-2141.1991.tb07968.x. [DOI] [PubMed] [Google Scholar]
  9. Cinatl J., Jr, Cinatl J., Gussetis E. S., Nemeth U., Mainke M., Kornhuber B., Brendel M., Doerr H. W. 2',3'-Dideoxycytidine preferentially inhibits in vitro growth of granulocyte-macrophage colony-forming cells from patients with chronic myeloid leukemia. Chemotherapy. 1991;37(2):128–133. doi: 10.1159/000238844. [DOI] [PubMed] [Google Scholar]
  10. Copeland W. C., Chen M. S., Wang T. S. Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem. 1992 Oct 25;267(30):21459–21464. [PubMed] [Google Scholar]
  11. Cretton E. M., Xie M. Y., Bevan R. J., Goudgaon N. M., Schinazi R. F., Sommadossi J. P. Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol. 1991 Feb;39(2):258–266. [PubMed] [Google Scholar]
  12. Du D. L., Volpe D. A., Grieshaber C. K., Murphy M. J., Jr In vitro myelotoxicity of 2',3'-dideoxynucleosides on human hematopoietic progenitor cells. Exp Hematol. 1990 Aug;18(7):832–836. [PubMed] [Google Scholar]
  13. Egeland T., Steen R., Quarsten H., Gaudernack G., Yang Y. C., Thorsby E. Myeloid differentiation of purified CD34+ cells after stimulation with recombinant human granulocyte-monocyte colony-stimulating factor (CSF), granulocyte-CSF, monocyte-CSF, and interleukin-3. Blood. 1991 Dec 15;78(12):3192–3199. [PubMed] [Google Scholar]
  14. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  15. Frick L. W., Nelson D. J., St Clair M. H., Furman P. A., Krenitsky T. A. Effects of 3'-azido-3'-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells. Biochem Biophys Res Commun. 1988 Jul 15;154(1):124–129. doi: 10.1016/0006-291x(88)90659-6. [DOI] [PubMed] [Google Scholar]
  16. Fridland A., Connelly M. C., Ashmun R. Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3'-azido-3'-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). Mol Pharmacol. 1990 May;37(5):665–670. [PubMed] [Google Scholar]
  17. Ganser A., Greher J., Völkers B., Staszewski S., Hoelzer D. Inhibitory effect of azidothymidine, 2'-3'-dideoxyadenosine, and 2'-3'-dideoxycytidine on in vitro growth of hematopoietic progenitor cells from normal persons and from patients with AIDS. Exp Hematol. 1989 May;17(4):321–325. [PubMed] [Google Scholar]
  18. Gogu S. R., Malter J. S., Agrawal K. C. Zidovudine-induced blockade of the expression and function of the erythropoietin receptor. Biochem Pharmacol. 1992 Sep 25;44(6):1009–1012. doi: 10.1016/0006-2952(92)90361-l. [DOI] [PubMed] [Google Scholar]
  19. Harrington J. A., Miller W. H., Spector T. Effector studies of 3'-azidothymidine nucleotides with human ribonucleotide reductase. Biochem Pharmacol. 1987 Nov 1;36(21):3757–3761. doi: 10.1016/0006-2952(87)90031-1. [DOI] [PubMed] [Google Scholar]
  20. Harrington J. A., Reardon J. E., Spector T. 3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNA. Antimicrob Agents Chemother. 1993 Apr;37(4):918–920. doi: 10.1128/aac.37.4.918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Hobbs G. A., Keilbaugh S. A., Simpson M. V. The Friend murine erythroleukemia cell, a model system for studying the association between bone marrow toxicity induced by 3'-azido-3'-dideoxythymidine and dideoxynucleoside inhibition of mtDNA replication. Biochem Pharmacol. 1992 Apr 1;43(7):1397–1400. doi: 10.1016/0006-2952(92)90194-n. [DOI] [PubMed] [Google Scholar]
  22. Johnson M., Caiazzo T., Molina J. M., Donahue R., Groopman J. Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives. Br J Haematol. 1988 Oct;70(2):137–141. doi: 10.1111/j.1365-2141.1988.tb02454.x. [DOI] [PubMed] [Google Scholar]
  23. Munch-Petersen B., Cloos L., Tyrsted G., Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 1991 May 15;266(14):9032–9038. [PubMed] [Google Scholar]
  24. Nickel W., Austermann S., Bialek G., Grosse F. Interactions of azidothymidine triphosphate with the cellular DNA polymerases alpha, delta, and epsilon and with DNA primase. J Biol Chem. 1992 Jan 15;267(2):848–854. [PubMed] [Google Scholar]
  25. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  26. Sato N., Sawada K., Kannonji M., Tarumi T., Sakai N., Ieko M., Sakurama S., Nakagawa S., Yasukouchi T., Krantz S. B. Purification of human marrow progenitor cells and demonstration of the direct action of macrophage colony-stimulating factor on colony-forming unit-macrophage. Blood. 1991 Aug 15;78(4):967–974. [PubMed] [Google Scholar]
  27. Sommadossi J. P., Carlisle R. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother. 1987 Mar;31(3):452–454. doi: 10.1128/aac.31.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sommadossi J. P. Nucleoside analogs: similarities and differences. Clin Infect Dis. 1993 Feb;16 (Suppl 1):S7–15. doi: 10.1093/clinids/16.supplement_1.s7. [DOI] [PubMed] [Google Scholar]
  29. Sommadossi J. P., Schinazi R. F., Chu C. K., Xie M. Y. Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells. Biochem Pharmacol. 1992 Nov 17;44(10):1921–1925. doi: 10.1016/0006-2952(92)90093-x. [DOI] [PubMed] [Google Scholar]
  30. Stagg M. P., Cretton E. M., Kidd L., Diasio R. B., Sommadossi J. P. Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine. Clin Pharmacol Ther. 1992 Jun;51(6):668–676. doi: 10.1038/clpt.1992.79. [DOI] [PubMed] [Google Scholar]
  31. Thompson M. B., Dunnick J. K., Sutphin M. E., Giles H. D., Irwin R. D., Prejean J. D. Hematologic toxicity of AZT and ddC administered as single agents and in combination to rats and mice. Fundam Appl Toxicol. 1991 Jul;17(1):159–176. doi: 10.1016/0272-0590(91)90248-3. [DOI] [PubMed] [Google Scholar]
  32. Vazquez-Padua M. A., Starnes M. C., Cheng Y. C. Incorporation of 3'-azido-3'-deoxythymidine into cellular DNA and its removal in a human leukemic cell line. Cancer Commun. 1990;2(1):55–62. doi: 10.3727/095535490820874740. [DOI] [PubMed] [Google Scholar]
  33. Weidner D. A., Bridges E. G., Cretton E. M., Sommadossi J. P. Comparative effects of 3'-azido-3'-deoxythymidine and its metabolite 3'-amino-3'-deoxythymidine on hemoglobin synthesis in K-562 human leukemia cells. Mol Pharmacol. 1992 Feb;41(2):252–258. [PubMed] [Google Scholar]
  34. Weidner D. A., Sommadossi J. P. 3'-Azido-3'-deoxythymidine inhibits globin gene transcription in butyric acid-induced K-562 human leukemia cells. Mol Pharmacol. 1990 Dec;38(6):797–804. [PubMed] [Google Scholar]
  35. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]
  36. Yarchoan R., Perno C. F., Thomas R. V., Klecker R. W., Allain J. P., Wills R. J., McAtee N., Fischl M. A., Dubinsky R., McNeely M. C. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988 Jan 16;1(8577):76–81. doi: 10.1016/s0140-6736(88)90283-8. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES